Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence to editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”

Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim

Clin Mol Hepatol. 2025;31(1):e70-e73. Published online September 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0761

View: 1241 Download: 64

Editorial

A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”

Johanna K. DiStefano, Glenn S. Gerhard

Clin Mol Hepatol. 2025;31(1):297-300. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0704

View: 1178 Download: 33 Crossref: 1

Reply to Correspondence

Reply to correspondence on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”

Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang

Clin Mol Hepatol. 2024;30(4):1037-1038. Published online May 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0320

View: 1852 Download: 56

Correspondence

Correspondence to editorial on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”

Yingzhou Shi, Guandou Yuan, Xiude Fan, Chao Xu

Clin Mol Hepatol. 2024;30(4):987-988. Published online April 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0266

View: 1822 Download: 47

Original Article

DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease

Amal Magdy, Hee-Jin Kim, Hanyong Go, Jun Min Lee, Hyun Ahm Sohn, Keeok Haam, Hyo-Jung Jung, Jong-Lyul Park, Taekyeong Yoo, Eun-Soo Kwon, Dong Hyeon Lee, Murim Choi, Keon Wook Kang, Won Kim, Mirang Kim, on behalf of the Innovative Target Exploration of NAFLD (ITEN) Consortium

Clin Mol Hepatol. 2024;30(4):824-844. Published online July 25, 2024

DOI: https://doi.org/10.3350/cmh.2024.0229

View: 3529 Download: 333 Web of Science: 4 Crossref: 3

Editorial

Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization

Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang

Clin Mol Hepatol. 2024;30(2):150-153. Published online February 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0116

View: 4314 Download: 96 Web of Science: 5 Crossref: 5

Original Article

Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets

Yingzhou Shi, Hang Dong, Shiwei Sun, Xiaoqin Wu, Jiansong Fang, Jianbo Zhao, Junming Han, Zongyue Li, Huixiao Wu, Luna Liu, Wanhong Wu, Yang Tian, Guandou Yuan, Xiude Fan, Chao Xu

Clin Mol Hepatol. 2024;30(1):80-97. Published online December 7, 2023

DOI: https://doi.org/10.3350/cmh.2023.0343

View: 6284 Download: 249 Web of Science: 6 Crossref: 3

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Roles of the complement system in alcohol-induced liver disease

Yi Zhou, Guandou Yuan, Fudi Zhong, Songqing He

Clin Mol Hepatol. 2020;26(4):677-685. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0094

View: 8649 Download: 154 Web of Science: 22 Crossref: 25

1 |

Viewed By 12435	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7602	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 7030	MAFLD: How is it different from NAFLD?
Viewed By 5648	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5498	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 366	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 348	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 232	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 116	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search